MedTrace Logo

Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects

NCT06232109 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-12-18

No results posted yet for this study

Summary

The drug-drug interaction study has been designed to investigate the effect of Fluvoxamine, Itraconazole and Paroxetine on the pharmacokinetics of ASN51

Conditions

  • Drug Drug Interaction

Interventions

DRUG

Fluvoxamine

Oral

DRUG

Itraconazole

Oral

DRUG

Paroxetine

Oral

DRUG

ASN51

Oral

Sponsors & Collaborators

  • Asceneuron S.A.

    lead INDUSTRY

Principal Investigators

  • Rolf Pokorny, MD · Asceneuron, SA

  • Jeroen v Wetering, MD · QPS Holdings LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-22
Primary Completion
2024-07-03
Completion
2024-07-03

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06232109 on ClinicalTrials.gov